Cardiome Development AG, a subsidiary of Cardiome Pharma Corp. has entered into an agreement with Tzamal Medical Ltd., to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Under the terms of the agreement, Tzamal Medical has agreed to specific annual commercial goals for Brinavess. Financial details of the agreement have not been disclosed.
“This agreement with Tzamal Medical reaffirms Cardiome’s commitment to continue making Brinavess available worldwide, including markets outside of Europe,” said Karim Lalji, Cardiome’s chief commercial officer. “We are pleased to have partnered with an industry leader and look forward to leveraging Tzamal Medical’s expertise to commercialize Brinavess in the Israeli market.”
“We are excited to be working with Cardiome to commercialize Brinavess in Israel,” said Edi Steinberg, CEO at Tzamal BioPharma Ltd, the pharmaceutical arm of Tzamal Medical Ltd. “Brinavess will be a great addition to our current line of hospital intensive and emergency care drug products. Emergency room physicians and surgeons need additional treatment options for Atrial Fibrillation (AF).”
The initial term of this commercial agreement begins September 15, 2013 for the duration of three years and is renewable on an annual basis, or longer, thereafter.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world.
Tzamal Medical Group is a leading private group of companies providing pharmaceuticals, medical devices and equipment for the healthcare industry with over 70 sales representative serving that market.